Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $12.37 $15.43 Thursday, 9th May 2024 URGN stock ended at $12.97. This is 2.26% less than the trading day before Wednesday, 8th May 2024. During the day the stock fluctuated 4.81% from a day low at $12.60 to a day high of $13.21.
90 days $12.37 $19.87
52 weeks $8.69 $24.13

Historical UroGen Pharma Ltd prices

Date Open High Low Close Volume
Mar 01, 2023 $10.36 $10.79 $10.29 $10.60 79 729
Feb 28, 2023 $10.20 $10.49 $10.07 $10.30 35 671
Feb 27, 2023 $9.78 $10.37 $9.78 $10.13 88 335
Feb 24, 2023 $10.42 $10.61 $9.67 $9.69 55 894
Feb 23, 2023 $9.94 $10.78 $9.83 $10.40 191 342
Feb 22, 2023 $9.49 $10.35 $9.44 $9.88 54 550
Feb 21, 2023 $10.12 $10.20 $9.20 $9.43 117 504
Feb 17, 2023 $9.42 $10.39 $9.36 $10.22 241 748
Feb 16, 2023 $9.03 $9.57 $9.03 $9.41 48 125
Feb 15, 2023 $9.29 $9.57 $9.11 $9.17 52 088
Feb 14, 2023 $9.44 $9.66 $9.19 $9.36 35 053
Feb 13, 2023 $9.16 $9.78 $9.16 $9.46 66 886
Feb 10, 2023 $8.80 $9.34 $8.67 $9.18 93 811
Feb 09, 2023 $9.11 $9.73 $8.80 $8.85 80 368
Feb 08, 2023 $8.91 $9.76 $8.88 $9.14 95 114
Feb 07, 2023 $9.07 $9.83 $8.92 $9.57 88 020
Feb 06, 2023 $9.27 $9.60 $9.16 $9.23 47 400
Feb 03, 2023 $10.71 $11.05 $8.89 $9.27 141 353
Feb 02, 2023 $11.01 $11.68 $10.79 $11.02 77 753
Feb 01, 2023 $10.40 $11.66 $10.09 $11.00 252 882
Jan 31, 2023 $10.00 $10.90 $9.90 $10.39 198 246
Jan 30, 2023 $9.42 $10.72 $9.42 $10.12 191 751
Jan 27, 2023 $8.40 $9.67 $8.40 $9.35 194 179
Jan 26, 2023 $8.12 $8.67 $8.01 $8.40 138 279
Jan 25, 2023 $8.00 $8.30 $7.60 $7.99 103 895
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT